A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

•Seladelpar (2, 5, 10 mg) was assessed in patients with primary biliary cholangitis.•ALP was dose-dependently reduced by 23% to 43% at Week 12.•ALP was normalized in 33% of patients in the 10 mg cohort at Week 52.•Up to 67% of patients met the composite ALP and bilirubin endpoint at Week 52.•Seladelpar was safe, with no treatment-related serious adverse events or deaths.